Of the 360 cases, high tumor mutation burden (TMB) was observed in 44 (12.2%), high microsatellite instability (MSI) was observed in 12 (3.33%) patients, ERBB2 amplification was observe in 44 (12.2%) patients, EBV positive was observed in 10 (10/278; 3.6%) patients, and PD-L1 positivity was observed in 186 (186/264; 70.5%) patients. This evidence concerns the gene CD274 and neoplasm.